胸腺肽联合拉米夫定治疗慢性乙型肝炎临床疗效.docVIP

胸腺肽联合拉米夫定治疗慢性乙型肝炎临床疗效[摘要] 目的：比较拉米夫定（3TC）与胸腺肽联用和单用拉米夫定治疗慢性乙型肝炎的疗效。方法：选择慢性乙型肝炎患者27例，分为联合组15例和拉米夫定组12例；联合组用拉米夫定100 mg，口服，qd，疗程半年，合并用胸腺肽100 mg，静滴，qd，疗程1个月。拉米夫定组单用拉米夫定。以谷丙转氨酶(ALT)、血清胆红素(TBIL)、乙肝病毒标志物(HBsAg，HBeAg，HBV-DNA)为观察指标，比较不同治疗方案对指标的影响。结果：治疗结束时联合组与拉米夫定组对慢性乙肝患者血清HBsAg阴转率分别是26.67％和16.67％(P＞0.05)；HBeAg阴转率分别是33.33％和8.33％(P＞0.05)；HBV-DNA阴转率分别是53.33％和33.33％(P＞0.05)。结论：胸腺肽联合3TC治疗慢乙肝，胸腺肽具有促进T淋巴细胞的成熟和转化，并维持免疫系统各T淋巴细胞亚群间的平衡作用，能增强成熟T淋巴细胞对抗原或其他刺激的反应。两者联合应用，旨在通过调节机体免疫力及抗病毒的双重作用，达到最大限度地清除病毒，预防和减少耐药毒株的产生。 [关键词] 慢性乙型肝炎；胸腺肽；拉米夫定 [中图分类号] R575.1 [文献标识码]B7[文章编号]1673-7210（2008）03（c）-056-02 The curative effect of combining Thymowin with Lamirudine to cure chronic hepatitis B ZHANG Shu-rong (Internal Department 3,the Peoples Hospital of Luliang,Yunnan Province，Luliang 655600,China) [Abstract] Objective:In order to compare the curative effects of using Lamirudine and Thymosin together with using Thymosin only to the paients of chronic hepatitis B.Methods:We had chosen 27 medical cases of chronic hepatitis B，which were divided into two groups：15 cases asone group(Group A)，and 12 cases as the other group(Group B).Let Group A take 100 mgLamirudine orally，qd，with half a year as a period of treatment.At the same time givethe patients injections of 100 mg Thymosin，qd，for a month.To Group B was only takenLamirudine.ALT，TBIL，the indicators of the virosis of hepatitis B (HBsAg，HBeAg,HBV-DNA)were observed as quatos.Results: At the end of the treatment, the rates that GroupA and Group B made HBsAg transform into negative were respectively 26.67% and 16.67%(P＞0.05)；HBeAg：33.33%,8.33%；HBV-DNA：53.33%，33.33%(P＞0.05).Conclusion:Combining thymic peptide with 3TC to treat chronic type B hepatitis, thymic peptide will not only promote B-cell to mature and transformation, but also to keep the subpopulation of T-cell in immune system in balance, which can enhance the reaction of matured T-cell to the antigen or other stimulus. In order to regulate the body’s immunity to resist the double-acti